Abstract: Disclosed herein are methods, systems, and devices for identifying increased likelihood of non-ST elevation myocardial infarction (NSTEMI) in a patient based on ECG data. The methods can include determining based on the ECG data that the patient lacks ST elevation (STE) and that the patient exhibits a ventricular repolarization dispersion (VRD) score that exceeds a predetermined threshold value. The VRD score can be based in part on a T wave complexity ratio that serves as a temporal marker of VRD for the patient. Other markers of spatial and time qualities of repolarization can also be included in the VRD score. An elevated VRD score in the absence of STE can indicate a likelihood of NSTEMI in the patient and a potential major adverse cardiac event.

Abstract: The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.

Abstract: A system for monitoring free flap patency includes transmit and receive transducers structured to be coupled to a blood vessel, and a plurality of circuitry modules structured to insonify a blood flow volume within the blood vessel and receive a scattered signal from the receive transducer, extract a baseband Doppler blood flow signal, VBASEBAND, from the scattered signal, extract a plurality of features from VBASEBAND, and classify the plurality of features and generate a binary signal based on the classification of the plurality of features, wherein the binary signal will have a first state responsive to the classification of the plurality of features indicating that a flow rate within the blood vessel is less than a predetermined level and a second state responsive to the classification of the plurality of features indicating the flow rate within the blood vessel is greater than or equal to the predetermined level.

Abstract: Provided herein are diaryl and arylalkyl phosphonates, useful as intermediates in, for example, the synthesis of leukocyte elastase inhibitors, potassium channel modulators, chemiluminescence materials, and flame retardants, and methods for making same. Also provided are N-heterocyclic phosphorodiamidic acids (NHPAs) useful in reactions such as, for example, in the preparation of diaryl and arylalkyl phosphonates. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: A two-wavelength, single-camera imaging thermography system for in-situ temperature measurement of a target, comprising: a target light path inlet conduit for receiving a target light beam reflected from the target; a beam splitter installed in a splitter housing at a distal end of the target light path conduit, wherein the beam splitter divides the target light beam into a first light beam and a second light beam; a first light path conduit emanating from the splitter housing comprising a first aperture iris installed within the first light path conduit for aligning the first light beam; a first band pass filter installed within the first light path conduit for regulating the first light beam to a first wavelength ?1 and an optional half waveplate installed within the first light path conduit to modulate a polarization ratio of the first light beam of ?1 wavelength; a second light path conduit emanating from the splitter housing comprising a second aperture iris installed within the second light path conduit

Abstract: Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gaucher's disease, and any disease or condition involving lysosomal storage dysfunction.

Abstract: Oncolytic viruses encoding a recombinant form of TGF-? engineered to prevent homodimerization and recruitment of TGF-? receptor I are described. The engineered TGF-? monomers function as dominant-negative TGF-? inhibitors. Oncolytic viruses encoding a TGF-? monomer can be used for cancer immunotherapy to inhibit the immunosuppressive tumor microenvironment.

Abstract: Devices and methods for multi-parameter hemodynamic monitoring are provided. Determining a cardiac output of a patient using a cuff device includes measuring a cuff pressure waveform of a subject during inflation and/or deflation of the cuff device, computing systolic and diastolic blood pressure from the cuff pressure waveform using the cuff device, constructing a blood pressure waveform from the systolic and diastolic blood pressure and cuff pressure waveform using the cuff device, computing brachial artery compliance from the cuff pressure waveform, and computing the cardiac output from the blood pressure waveform and/or brachial artery compliance using the cuff device.

Abstract: Methods are disclosed herein for efficiently generating human induced pluripotent stem cells (iPSC) containing a nucleic acid including a doxycycline promoter operably linked to a nucleic acid encoding Cas9. These methods include transfecting a human somatic cell with a nucleic acid molecule comprising a doxycycline promoter operably linked to a nucleic acid encoding a Cas9, and constitutive promoter operably linked to a tetracycline responsive element and inducing the somatic cell to form an iPSC, thereby producing an iPSC that can undergo CRISPR/Cas9-mediated recombination at a high efficiency. The human iPSC, or a cell differentiated therefrom, is cultured in the presence of doxycycline to induce expression of the Cas9. These cells can then be used to target in any gene of interest by introducing nucleic acids encoding sgRNAs. Induced pluripotent stem cells produced by these methods are also disclosed.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.

Abstract: Provided herein is a method of blocking a nerve or neuron by applying an electrical stimulation to the nerve or neuron, wherein the electrical stimulation is of an intensity below the excitation threshold of the nerve or neuron for a length of time sufficient to produce a block of nerve conduction or neuron excitation.

Abstract: A method of reducing an aromatic ring or a cyclic, allylic ether in a compound includes preparing a reaction mixture including a compound including an aromatic moiety or a cyclic, allylic ether moiety, an alkali metal, and either ethylenediamine, diethylenetriamine, triethylenetetramine, or a combination thereof, in an ether solvent; and reacting the reaction mixture at from ?20° C. to 30° C. for a time sufficient to reduce a double bond in the aromatic moiety to a single bond or to reduce the cyclic, allylic ether moiety.

Abstract: Provided herein are compositions and methods for therapeutic and/or prophylactic treatment of an intracellular bacterial infection in a subject in need thereof, comprising one or more modulating agents, wherein the one or more modulating agents increase expression of IFN?, IL-2, TNF, and/or IL-17 in systemic and/or lung T cells. In some embodiments, the increase of expression of IFN?, IL-2, TNF, and/or IL-17 occurs in lung T cells. The lung T cells can be lung resident T cells or systemic T cells that are recruited to the lung. In some embodiments, the T cells are CD4+ and/or CD8+ T cells. In some embodiments, the intracellular bacterial infection is a Mycobacterium tuberculosis (MTB) infection.

Abstract: Devices and methods for determining blood pressures are provided. In one example, a device for determining blood pressure of a subject includes a camera configured to measure a finger photo-plethysmography (PPG) waveform, an accelerometer configured to measure a vertical height of the device relative to a heart of a subject, an output device configured to guide the subject to raise a hand to vary the transmural pressure of an artery while maintaining a finger pressure on the camera, and a processor configured to compute pulse pressure of the subject from the finger PPG waveform and the vertical height, and display the pulse pressure on the screen.

Abstract: A machine-implemented method, computing device, and at least one non-transitory computer-readable medium are provided. A dynamical network model is parameterized by state transition matrices based on monitored interictal brain data. A node influence-to network score for each respective node is calculated indicating how influential the respective node is. An influenced-by score is calculated for the each respective node indicating an amount by which the respective node is influenced by the nodes. A score is calculated for the each respective node based on a sink index, a source influence index, and a sink connectivity index. Nodes that are in the epileptogenic zone are determined based on the calculated score for each of the nodes. An indication of the nodes in the epileptogenic zone is provided.

Abstract: The present invention provides a multivalent compound for targeted molecular imaging and/or targeted drug delivery, wherein two components or targeting molecules each interacts with one or more biomarkers on a cell. The present invention further provides a multifunctional chelator to combine the targeting molecules. The present invention also provides an in vitro high-throughput screening assay to determine the length of the spacer molecules. The present invention also relates to compounds/probes, kits and methods for use in targeted molecular imaging and/or targeted drug delivery.

Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

Abstract: A formulation includes a plurality of polymers including a hydrophobic polymer backbone (for example, formed via radical polymerization), a first plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one cationic group, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one hydrophilic polymer, a first therapeutic compound, and a second therapeutic compound, wherein the second therapeutic compound is different from the first therapeutic compound and includes a nucleic acid.

Abstract: Provided herein are small molecules that specifically inhibit TNF-induced nuclear factor kB (NF-kB) inflammation pathway. Also provided are methods of screening compounds to identify molecules that specifically inhibit a TNF-induced NF-kB inflammation pathway, methods of inhibiting TNF-induced NF-kB inflammation pathway, and methods of preventing formation of mature TNFR1 complex.